http://www.contrarianprofits.com/articles/sinuvac-sva-reports-swine-flu-success/20000 Access market-beating ideas from the world's top investment gurus on stock market investing, the gold market, ETFs, Forex trading and real estate values. Tue, 18 May 2010 05:09:46 -0500 http://wordpress.org/?v=2.8.5 hourly 1 http://www.contrarianprofits.com/articles/sinuvac-sva-reports-swine-flu-success/20000/comment-page-1#comment-61737 Jerry2665 Wed, 19 Aug 2009 02:59:50 +0000 http://www.contrarianprofits.com/?p=20000#comment-61737 Sinovac Biotech Ltd. announced the positive top line results from the completed clinical trial for its internally developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. The analysis of the clinical trial results showed that the H1N1 vaccine developed by Sinovac induces good immunogenicity after one dose. The seropositive rate, seroconvertive rate and GMT increasing multiple have reached the international criteria for vaccines, which indicates that Sinovac's H1N1 vaccine has good immunogenicity and offers protection. After receiving one shot of the vaccine, none of the volunteers participating in Sinovac's clinical trials exhibited any signs of severe adverse reactions. The adverse events were all mild and transient, with pain at the site of injection as common symptom. The total adverse event rate is similar to the seasonal influenza vaccine. These results demonstrated that the H1N1 vaccine has a good safety profile. Sinovac Biotech Ltd. announced the positive top line results from the completed clinical trial for its internally developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. The analysis of the clinical trial results showed that the H1N1 vaccine developed by Sinovac induces good immunogenicity after one dose. The seropositive rate, seroconvertive rate and GMT increasing multiple have reached the international criteria for vaccines, which indicates that Sinovac’s H1N1 vaccine has good immunogenicity and offers protection. After receiving one shot of the vaccine, none of the volunteers participating in Sinovac’s clinical trials exhibited any signs of severe adverse reactions. The adverse events were all mild and transient, with pain at the site of injection as common symptom. The total adverse event rate is similar to the seasonal influenza vaccine. These results demonstrated that the H1N1 vaccine has a good safety profile.

]]>